Ermis Necip, Atalay Hakan, Altay Hakan, Bilgi Muhammet, Binici Suleyman, Sezgin Alpay T
Cardiology Department, Nonu University, Turgut Özal Medical Center, Elazıg yolu 15.km, Malatya, Turkey.
Heart Surg Forum. 2011 Apr;14(2):E87-92. doi: 10.1532/HSF98.20101062.
Prosthetic heart valve thrombosis (PVT) is a rare but severe cardiac condition. There are only a few data regarding comparison of the fibrinolytic and surgical approaches for the treatment of PVT. In this study, we compared the results of fibrinolytic therapy versus surgery in patients who presented to our institution with a diagnosis of obstructive-type PVT.
From January 2001 to August 2008 in our institution, 33 patients who met clinical and echocardiographic criteria for obstructive-type PVT were included in the study. Fifteen of these patients underwent fibrinolytic treatment with streptokinase, which consisted of an initial bolus of 250,000 U followed by 100,000 U/h. Eighteen patients were treated with surgery.
The 2 groups had similar baseline characteristics, including New York Heart Association functional status, types and positions of prosthetic valves, international normalized ratio values, and presentation symptoms. Full hemodynamic success was achieved in 12 patients who underwent fibrinolytic therapy and in 15 patients in the surgery group. The mean (±SD) streptokinase infusion time was 17.8 ± 11.1 hours. Two major hemorrhages and 2 cases of systemic embolism were observed in the fibrinolytic group. The 2 groups did not differ with respect to mortality rate (P = .79). The duration of hospitalization was longer in the fibrinolytic group than in the surgery group (10.7 ± 6.6 days versus 6.9 ± 6.7 days, P = .045).
Although fibrinolytic therapy is generally recommended for the treatment of PVT for specific patient groups, our results suggest that it may be as efficacious and safe as surgery, depending on patient selection.
人工心脏瓣膜血栓形成(PVT)是一种罕见但严重的心脏疾病。关于纤维蛋白溶解疗法和手术方法治疗PVT的比较,仅有少量数据。在本研究中,我们比较了纤维蛋白溶解疗法与手术治疗在我院诊断为梗阻型PVT患者中的结果。
2001年1月至2008年8月期间,我院33例符合梗阻型PVT临床和超声心动图标准的患者纳入研究。其中15例患者接受链激酶纤维蛋白溶解治疗,初始剂量为250,000 U推注,随后以100,000 U/h持续输注。18例患者接受手术治疗。
两组患者的基线特征相似,包括纽约心脏协会心功能分级、人工瓣膜类型和位置、国际标准化比值以及临床表现。接受纤维蛋白溶解治疗的12例患者和手术组的15例患者实现了完全血流动力学成功。链激酶平均(±标准差)输注时间为17.8±11.1小时。纤维蛋白溶解组观察到2例严重出血和2例全身性栓塞。两组死亡率无差异(P = 0.79)。纤维蛋白溶解组住院时间长于手术组(10.7±6.6天对6.9±6.7天,P = 0.045)。
尽管通常建议对特定患者群体采用纤维蛋白溶解疗法治疗PVT,但我们的结果表明,根据患者选择,它可能与手术一样有效和安全。